Advancing To Next Dosing Cohort in Severe Alcoholic Hepatitis (AH) Patients Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 7, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2018 and provided a corporate update. Total revenues were […]
CUPERTINO, Calif., March 4, 2019 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 7, 2019 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast
DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call Read More »
Live Webcast Today at 10:30 a.m. Eastern Time CUPERTINO, Calif., Feb. 27, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has completed a comprehensive review of its POSIMIR® (bupivacaine extended-release solution) program and plans to submit a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration
CUPERTINO, Calif., Feb. 21, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019, at Berenberg’s New York City offices. The format for the day includes an introductory session, a
DURECT Corporation to Participate in the Berenberg NASH Day Read More »
Live Webcast Today at 8:00 a.m. Eastern Time CUPERTINO, Calif., Jan. 7, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) has refined and focused its clinical development strategy for DUR-928, the lead product candidate in its Epigenetic Regulator Program, to prioritize indications with unmet medical needs where we expect to be able to generate near-term data with
DURECT Corporation Provides Corporate Update Read More »
CUPERTINO, Calif., Jan. 3, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) invites interested parties to listen to a corporate update conference call that will be broadcast live over the internet on Monday, January 7, 2019 at 8:00 am Eastern Time (5:00 am Pacific Time). A live audio webcast of the presentation will be available by accessing
DURECT Corporation Announces Investor Call to Provide Corporate Update Read More »
Indivior PLC Announces Plan for Commercial Launch in February 2019 with 50 Sales Representatives CUPERTINO, Calif., Dec. 19, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) stated on December 18, 2018 that it is moving ahead with the launch of PERSERIS™ in the U.S. with a sales force consisting of approximately
David Hoffmann, Current Lead Independent Director and Chairman of the Audit Committee, to Assume Position of Chairman of the Board CUPERTINO, Calif., Dec. 17, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes will retire as Chairman of the Board and Distinguished Scientist effective December 31, 2018. Dr. Theeuwes has been scaling back
CUPERTINO, Calif., Nov. 19, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients with alcoholic hepatitis (AH) to accelerate the initiation of dosing of severe AH patents. The Company recently completed dosing for the low-dose 30 mg cohort (n=4) of Part
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., Nov. 7, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2018 and provided a corporate update. Total revenues were $8.0 million and net loss was $2.7 million for the three months ended
